Due to health issues, this site is no longer maintained and will be shut down shortly.

MESO Mesoblast ADRs

Mesoblast Ltd is engaged in the development of biologic products for the broad field of regenerative medicine. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. This is an ADR of a company whose stock trades outside of the U.S. as the symbol AT:MSB.

$3.17  +0.08 (2.59%)
As of 03/27/2023 12:45:00 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Australia
Country of incorporation:  Australia
IPO date:  01/18/2006
Outstanding shares:  147,424,244
Average volume:  204,750
Market cap:   $464,386,369
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy